Immune responses can make protein therapeutics ineffective or even dangerous. We describe a general computational protein design method for reducing immunogenicity by eliminating known and predicted T-cell epitopes and maximizing the content of human peptide sequences without disrupting protein structure and function. We show that the method recapitulates previous experimental results on immunogenicity reduction, and we use it to disrupt T-cell epitopes in GFP and Pseudomonas exotoxin A without disrupting function.mmunogenicity is a major problem in the development of protein therapeutics. Repeated administration of a protein therapeutic can lead to B-cell activation and production of antibodies, rendering the therapeutic clinically ineffective or cross-reacting with host proteins (1). Affinity maturation of antibody-producing memory B cells is initiated by T-cell recognition of peptide epitopes displayed on major histocompatibility complex class II (MHCII) proteins on the surface of mature antigen-presenting cells. Immunogenicity may be reduced by eliminating known T-cell epitopes from the protein sequence and/or increasing the prevalence of sequences already found in the host genome to which T cells would already be tolerant, an approach that has met with substantial clinical success in the humanization of recombinant antibodies (2). However, unlike antibodies, which have been extensively characterized, the mutational tolerance of most proteins is generally not known, and hence, the extension of this approach to proteins of arbitrary structure and function remains a major challenge. Deimmunization efforts have relied, for the most part, on experimental characterization of a large number of point mutants followed by a combination of individual mutations (3, 4).To reduce or eliminate immunogenicity, it would be desirable to have a method that eliminates MHCII-binding epitopes and increases host sequence content without disrupting interactions essential for proper folding and function. The peptide-binding repertoire of many MHCII alleles has been extensively characterized (5), and a number of methods has been developed for predicting the affinity of novel peptides for a given MHCII (6). Coupling of epitope prediction methods with methods for predicting the structural and functional consequences of mutations offers the possibility of reducing the immunogenicity of a target protein without disrupting structure and function. Epitope prediction methods, homolog substitution matrices, and structural stability calculations have been combined to predict optimal epitope-eliminating mutations (7,8). Epitope prediction methods have been integrated with structure-based protein design (9) by combining the 9mer epitope PROPRED matrices with protein design of all residues in a flexible backbone method that allows substantial redesign of protein cores. The combined method was able to eliminate epitope-like sequences while maintaining native-like values for a number of predicted protein stability metrics, but folding, function, ...